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and older). The impact of arthritis on physical unhealthy days
was stronger among those aged 45–64. (Odds Ratio (OR) = 2.1
for aged 18–44; OR = 3.1 for aged 45–64; OR = 2.1 for aged
65 and older). Unlike a physical unhealthy day, younger people
were more likely to experience a mental unhealthy day in the
general adult population (42.0% for 18–44 years old; 33.4% for
45–64 years old; 17.8% for 65 and older). The impact of arthri-
tis on having mental “unhealthy day” was also stronger among
those aged 45–64 (OR = 1.8 for aged 18–44; OR = 2.3 for aged
45–64; OR = 1.3 for aged 65 and older). CONCLUSION: The
data shows that arthritis has a signiﬁcant impact on the experi-
ence of physical or mental unhealthy days. Although arthritis is
more prevalent among adults aged 65 and older, its impact on
mental “unhealthy days” was stronger among younger adults.
These ﬁndings should be considered in implementing public
health programs.
CANCER—Clinical Outcomes Studies
PCN1
COLONIC STENTING VERSUS SURGERY FOR MALIGNANT
LARGE BOWEL OBSTRUCTION: COMPARATIVE ASSESSMENT
OF OUTCOMES AND COST
Bapat B1, Subramanian S2
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OBJECTIVES: Colorectal cancer is the third most common
malignant neoplasm worldwide and the second leading cause of
cancer deaths in the United States. Advanced colorectal cancer
often presents as large bowel obstruction. With colonic stenting
the creation of a stoma can be avoided and procedural mortal-
ity can be reduced. The objective of this study is to compare the
outcomes and cost of colonic stenting compared to surgery for
large bowel obstruction. METHODS: We used the 2001
Medicare Standard Analytic Files to identify patients who under-
went colon stenting and surgery for large bowel obstruction
caused by colorectal cancer using a combination of procedure
codes and diagnosis codes. For each patient we analyzed the ﬁrst
stenting procedure (index event) we identiﬁed.. We summarized
patients’ demographic characteristics including age, sex and race.
Outcomes and resource utilization measures (inpatient and out-
patient costs, ER visits, in-hospital mortality, and length of stay)
were computed for the index hospitalization and 90-day follow-
up period. RESULTS: We identiﬁed 212 patients with stent
placements and 969 who underwent surgical intervention. The
two groups were similar in demographics and risk factors. In-
hospital mortality was lower for the stent group compared to the
surgery group but this difference was not statistically signiﬁcant
(8.0% versus 11.4%; p = 0.156). Emergency room visits during
the 90 day follow-up period was signiﬁcantly higher for the
surgery group (11.3% versus 17.0%; p = 0.040). Adjusted cost
for the 90-day follow-up period was $6726 (p = 0.000) lower
for the stent group compared to the surgery group. The 90-day
mortality was similar for the two groups CONCLUSION:
Patients who underwent stent placements appear to have fewer
complications during follow-up as they require fewer emergency
room visits. Stent placement appears to be less expensive than
surgery. Additional analysis with larger sample size and longer
follow-up is required to conﬁrm the results from this study.
PCN2
ASSESSING THE NET HEALTH OUTCOMES OF A 4D
ELECTROMAGNETIC TUMOR TRACKING SYSTEM DURING
RADIOTHERAPY FOR CLINICALLY LOCALIZED PROSTATE
CANCER:A HEALTH TECHNOLOGY ASSESSMENT OF THE
CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON®
TRANSPONDERS
Williams E, Najib MM
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OBJECTIVES: Without accurate tumor localization, radiother-
apeutic efﬁcacy is suboptimal and sources of geometric varia-
tions, such as organ motion and patient movement, can result in
irradiation of normal tissues. An evidence-based health technol-
ogy assessment evaluated whether using a real-time 4D electro-
magnetic tumor tracking system, (Calypso® 4D Localization
System with Beacon® Transponders; “Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington), improves
the net health outcomes of patients irradiated for clinically local-
ized prostate cancer. METHODS: We addressed the following
questions: 1) Does the Calypso® 4D Localization System accu-
rately localize prostate tumors? 2) Does real-time 4D electro-
magnetic tracking reduce radiation-induced toxicity? 3) How do
the outcomes of real-time 4D electromagnetic tracking compare
to those of alternative technologies? Comparators included 
electronic portal imaging devices, computed tomography, 
ultrasound, and stereoscopic X-ray. We searched electronic 
bibliographic databases and systematically reviewed studies
reporting target shifts between treatment and linear accelerator
isocenters, percentages of shifts exceeding tolerable limits, radi-
ation-induced toxicities, and quality of life measurements.
Unpublished data on the Calypso® 4D Localization System were
also reviewed. RESULTS: Based on 1027 intra-subjects compar-
isons, the Calypso® 4D Localization System was statistically sig-
niﬁcantly (P < 0.0001) concordant with standard radiographic
localization. One prospective multicenter clinical trial showed
that the Calypso® 4D Localization System detected clinically
meaningful misalignments in 1174 of 1524 (77%) treatments for
41 patients positioned by conventional lasers and skin tattoos.
Complications from Beacon® Transponders placement were
comparable to those of transrectal biopsy and prostatic ﬁducial
implantation. Fifteen of 41 (35%) patients experienced minor
acute bladder toxicities; none experienced acute rectal compli-
cations. CONCLUSION: Published evidence suggests that real-
time 4D tracking confers greater accuracy than alternative
methods, but head-to-head clinical trials are lacking and there
are currently no alternative methods for real-time tumor track-
ing. This technology may also reduce overall treatment-related
morbidity; however, we await mature data on late toxicities and
tumor control.
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OBJECTIVES: The relationship between disease progression
endpoints and overall survival (OS) has been demonstrated in
colorectal, colon and non-small lung cancers (Johnson et al.
Lancet 2006; Sargent et al. JCO 2005). Patient access to novel
and efﬁcacious therapies for metastatic breast cancer (MBC)
could be expedited if disease progression was documented as a
valid surrogate outcome for OS in pivotal clinical trials. We
assessed the correlation between time to tumor progression
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(TTP) and progression-free survival (PFS) and OS in randomized
controlled trials (RCTs) for MBC. METHODS: A literature
search was conducted to retrieve all RCTs since 1994 in patients
with MBC (ﬁrst line and refractory) in which both progression
endpoints and OS were reported. Summary data, trial and
patient characteristics were abstracted and data analyzed using
Spearman correlation coefﬁcients and simple regression equa-
tions, similar to the approach used by Louvet et al. (Cancer
2001) for colorectal cancer. RESULTS: Of 582 study citations
retrieved, 68 met all eligibility criteria, including a total of
∼19,000 patients. Among 51 studies, reported TTP across treat-
ment groups averaged 6.9 months and OS averaged 20.5
months. Correlation between measures was 0.33 (p = 0.0007).
An additional 17 studies provided PFS (mean = 7.3 months).
However, deﬁnitions provided for TTP and PFS were not con-
sistent across studies and often overlapped. When all studies
were included and OS was compared to TTP or PFS, correlation
was 0.31 (p = 0.0002). Linear regression coefﬁcients suggest that
a 1-month increase in TTP or PFS corresponds to a commensu-
rate increase in OS (slope = 0.9). CONCLUSION: These results
suggest that increases in time to progression endpoints (TTP/PFS)
observed in MBC trials ultimately correspond to survival bene-
ﬁts as previously established in other tumor types. This ﬁnding
is particularly important since survival data from RCTs is often
obscured by subsequent treatments or patient cross-over.
CANCER—Cost Studies
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OBJECTIVES: To assess the ﬁnancial consequences of the intro-
duction of trastuzumab as adjuvant therapy for HER2-positive
early breast cancer (EBC) patients in Poland. METHODS: The
analysis was perfomed using modelling technique, based on
Polish epidemiologic data and cost estimates. Only direct
medical costs were included and assessed from health care payer
perspective. The baseline risk of disease progression and the
impact of trastuzumab on disease progression were taken from
HERA study. After determining the number of patients on
therapy expected over the 2007–2009 time horizon, the model
determines the cost of therapy in a scenario where trastuzumab
is not available in Poland (A) and a scenario where trastuzumab
is available (B). The model then calculates the trastuzumab-
related budget impact as the incremental costs associated with
The rapy in the population between the two scenarios consid-
ered above. Extreme scenario sensitivity analyses were per-
formed. RESULTS: According to epidemiologic data the
expected number of patients eligible for trastuzumab adjuvant
therapy would be 932 for each year between 2007–2009. Results
of the budget impact analysis suggest that expenditures are
expected to evolve with the introduction of trastuzumab in
Poland, from 60,057,901 PLN in 2007 to 119,415,721 PLN in
2008 and 117,662,121 in 2009, and between 2007–2009 would
increase by 297,135,743 PLN in total. Such an increase in cost
would be associated with acquisition and administration cost of
trastuzumab and would be only partially compensated by lower
costs of metastatic and recurrence health states in scenario B.
Sensitivity analysis shows that in all scenarios introduction of
trastuzumab as adjuvant therapy for HER2-positive EBC
patients requires the additional budget assessed at 253,772,456
PLN-302,924,889 PLN for the period 2007–2009. CONCLU-
SION: The increase in costs associated with the introduction of
trastuzumab as adjuvant therapy needs to be considered along-
side with improved clinical effectiveness for patients treated with
trastuzumab.
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PHARMACOECONOMIC ANALYSIS OF SORAFENIB AND
SUNITINIB FOR FIRST LINE TREATMENT OF METASTATIC
RENAL CELL CARCINOMA (MRCC) COMPARED WITH
COMBINATION THERAPY OF BEVACIZUMAB, GEMCITABINE,
AND CAPECITABINE (BGC) AT A LARGE CANCER CENTER
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OBJECTIVES: To evaluate the pharmacoeconomics, including
cost-effectiveness and budget impact, of the addition of 2 novel
treatments for MRCC in the Formulary of a large teaching
cancer center. METHODS: Prior to the FDA’s approval of
sorafenib and sunitinib, a majority of patients with MRCC
treated at our center received the BGC regimen. Sorafenib and
sunitinib were FDA-approved for MRCC in December 2005 and
January 2006 respectively. We created a pharmacoeconomic
model to characterize the expected use of sorafenib and sunitinib
compared to the traditional BGC therapy. The model was created
assuming equal use of both new agents (40%) and modest use
of the BGC regimen (20%). The time-to-progression (TTP) used
to calculate cost-effectiveness was based on clinical experience
at our institution (expert opinion) and clinical trials. The model
also accounts for the development of adverse events requiring
dose reductions based on our experience. Other parameters used
were average wholesale price (AWP), BSA = 2 m2, and average
weight = 70 kilograms. RESULTS: Approximately 144 patients
per year with MRCC receive treatment at our institution. The
institutional cost-effectiveness of these regimens is as follows:
sorafenib = $54,000/PFS-year; sunitinib = $59,000/PFS-year, and
BGC = $152,000/PFS-year. The overall budget impact of the
introduction of these 2 agents was a decrease in $3 million per
year in total drug costs to treat MRCC when compared to the
BCG regimen. CONCLUSION: Sorafenib and sunitinib offer
alternative treatment for MRCC and are associated with better
outcomes (longer TTP) and convenience (oral therapy). This was
important for our institution because bevacizumab, the most
costly agent in the BGC regimen, has not received FDA approval
for the treatment of MRCC and therefore, reimbursement for
this indication is limited. Sorafenib and sunitinib offer a supe-
rior treatment option at a lower cost and potential for improved
revenue.
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A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY
WITH EXEMESTANE,ANASTROZOLE, LETROZOLE OR
TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY-
STAGE BREAST CANCER IN MEXICO
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OBJECTIVES: In Mexico, breast cancer is the most common
tumour in women and by 2010 local estimations forecast that
more than 200 thousand Mexican women would need attention
due to this disease. The purpose of this study was to evaluate the
